The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective

Abstract

BackgroundChronic hepatitis C virus (HCV) may progress to advanced liver disease (ALD), including decompensated cirrhosis and/or hepatocellular carcinoma (HCC). ALD can lead to significant clinical and economic consequences, including liver transplantation. This study evaluated the health care costs associated with ALD among HCV infected patients in a Medicaid population.MethodsUsing Florida Medicaid claims data, cases were patients with at least 1 diagnosis of HCV or prescription therapy for HCV (ribavirin plus interferon, peginterferon, or interferon alfacon-1) prior to an incident ALD-related diagnosis (“index event”) between 1999 and 2007. ALD-related conditions included decompensated cirrhosis, HCC, or liver transplant. A cohort of HCV patients without ALD (comparison group subjects) were matched 1-to-1 based on age, sex, and race. Baseline and follow-up were the 12 months prior to and following index, respectively; with both periods allowing for a maximum one month gap in eligibility. For both case and comparison patient cohorts, per-patient-per-eligible month (PPPM) costs were calculated as total Medicaid paid amount for each patient over their observed number of eligible months in follow-up, divided by the patient’s total number of eligible months. A generalized linear model (GLM) was constructed controlling for age, race, Charlson score, alcoholic cirrhosis, and hepatitis B to explore all-cause PPPM costs between study groups. The final study group included 1,193 cases and matched comparison patients (mean age: 49 years; 45% female; 54% white, 23% black, 23% other).ResultsThe majority of ALD-related diagnoses were for decompensated cirrhosis (92%), followed by HCC (6%) and liver transplant (2%). Cases had greater comorbidity (mean Charlson score: 3.1 vs. 2.3, P < 0.001). All-cause inpatient use up to 1-year following incident ALD diagnosis was significantly greater among cases with ALD (74% vs. 27%, P < 0.001). In the GLM, cases had 2.39 times greater total adjusted mean all-cause PPPM costs compared to the comparison group ($4,956 vs. $1,735 respectively; P < 0.001). Among cases, mean total unadjusted ALD-related costs were $1,356 PPPM, which were largely driven by inpatient costs ($1,272).ConclusionsOur results suggest that among patients diagnosed with HCV, the incremental costs of developing ALD are substantial, with inpatient stays as the main driver of these increased costs.

Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation

“…The three factors that had the highest contribution to total cost for in‐patients were the presence of ESRD, presence of HCV and higher mean Charlson score; the three factors that had the highest contribution to total cost for out‐patients were the presence of ESRD, high mean Charlson score and being disabled. Our findings are consistent with prior studies . Also, Galbraith et al .…”

Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States

“…In this study, we found that, as a potential cost‐saving measure under Medicare‐managed care, patients were discharged sooner and, if unable to go home with or without assisted help, were discharged to a care facility for further treatment. This was especially true for HCV patients categorized into the extreme illness category who were almost six times more likely to be discharged to an intermediate care facility and approximately three times more likely to be discharged to home with home health care . These data may help explain the contradictory finding of higher charges but no increase in hospital costs or in a patient's length of stay.…”

“…The economic impact of HCV‐related healthcare costs has been studied by both Menzin and colleagues and Gordon with his co‐investigators . They found healthcare costs increased with the severity of illness and was the highest for those with end‐stage liver disease.…”

Engaging hepatitis C infected patients in cost‐effectiveness analyses: A literature review

“…Chronic hepatitis C virus (HCV) is estimated to affect more than 3 million Americans and is characterized by both hepatic and extrahepatic manifestations that can impact patients' lives . In terms of direct economic burden, substantial costs are historically associated with advanced disease and inpatient care . Recent innovations in drug therapy provide the opportunity for clinical cure of this chronic infection.…”